Major Depressive Disorder

Last updated: November 29, 2023
Sponsor: Relmada
Overall Status: Active - Recruiting

Phase

3

Condition

N/A

Treatment

N/A

Clinical Study ID

TX322048
REL-1017-302
  • Ages 18-65
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

A Phase 3, multicenter, randomized, double-blind study to assess the efficacy and safety of study medication for Major Depressive Disorder.

Eligibility Criteria

Inclusion

Inclusion Criteria

  • Male or Female 18-65 years old
  • BMI between 18-30.0 kg
  • Diagnosed with MDD (Major Depressive Disorder)
  • Stabilized for at least 6 weeks on depression medication
  • No poorly controlled diabetes
  • No use of St. Johns Wort within 30 days prior to screening
  • No cancer in the last 4 years
  • No planned elective surgery requiring general anesthesia
  • No gastric bypass surgery

Study Design

Study Start date:
November 17, 2023
Estimated Completion Date:

Study Description

This study is 42 days in duration with 8 in office visits.

Connect with a study center

  • Elite Clinical Studies

    Phoenix, AZ 85018
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.